During the last session, VBI Vaccines Inc. (NASDAQ:VBIV)’s traded shares were 1.97 million, with the beta value of the company hitting 2.02. At the end of the trading day, the stock’s price was $3.15, reflecting an intraday gain of 2.27% or $0.07. The 52-week high for the VBIV share is $6.13, that puts it down -94.6 from that peak though still a striking 34.29% gain since the share price plummeted to a 52-week low of $2.07. The company’s market capitalization is $806.21M, and the average trade volume was 3.35 million shares over the past three months.
VBI Vaccines Inc. (VBIV) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.00. VBIV has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.06.
VBI Vaccines Inc. (NASDAQ:VBIV) trade information
VBI Vaccines Inc. (VBIV) registered a 2.27% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.27% in intraday trading to $3.15 this Wednesday, 07/21/21, hitting a weekly high. The stock’s 5-day price performance is 6.06%, and it has moved by -17.54% in 30 days. Based on these gigs, the overall price performance for the year is -41.56%.
The consensus price target of analysts on Wall Street is $8.00, which implies an increase of 60.62% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.00 and $9.00 respectively. As a result, VBIV is trading at a discount of -185.71% off the target high and -122.22% off the low.
VBI Vaccines Inc. (VBIV) estimates and forecasts
Statistics show that VBI Vaccines Inc. has underperformed its competitors in share price, compared to the industry in which it operates. VBI Vaccines Inc. (VBIV) shares have gone down -4.40% during the last six months, with a year-to-date growth rate less than the industry average at -42.86% against 8.80. In the rating firms’ projections, revenue will increase 204.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $480k as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $550k by the end of Sep 2021.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 28.90%. While earnings are projected to return 53.80% in 2021.
VBI Vaccines Inc. is due to release its next quarterly earnings between July 29 and August 02. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
VBI Vaccines Inc. (NASDAQ:VBIV)’s Major holders
VBI Vaccines Inc. insiders own 0.53% of total outstanding shares while institutional holders control 53.24%, with the float percentage being 53.52%. Perceptive Advisors Llc is the largest shareholder of the company, while 193 institutions own stock in it. As of Mar 30, 2021, the company held over 55.04 million shares (or 21.65% of all shares), a total value of $171.18 million in shares.
The next largest institutional holding, with 18.68 million shares, is of State Street Corporation’s that is approximately 7.35% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $58.1 million.
Also, the Mutual Funds coming in first place with the largest holdings of VBI Vaccines Inc. (VBIV) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and iShares Russell 2000 ETF. Data provided on May 30, 2021 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 15.51 million shares. This amounts to just over 6.10 percent of the company’s overall shares, with a $50.08 million market value. The same data shows that the other fund manager holds slightly less at 4.24 million, or about 1.67% of the stock, which is worth about $13.71 million.